October 13, 2015 / 12:51 PM / 4 years ago

Zosano says blood sugar patch meets study goal

(Reuters) - Drug developer Zosano Pharma Corp said a mid-stage study testing its experimental patch to treat low blood sugar met the main goal.

The company said the patch, ZP-Glucagon, normalized blood sugar in all the patients who received it.

ZP-Glucagon is the lead treatment that Zosano is developing. The company is also developing a therapy for osteoporosis in early studies.

The company said on Tuesday the study compared ZP-Glucagon to an intramuscular injection that is meant to reverse low-blood sugar in patients who are given insulin to treat Type 1 diabetes.

Zosano said the patch was well-tolerated.

Up to Monday’s close, the Fremont, California-based company’s shares had lost about 75 percent of their value since they went public on Jan. 27.

Reporting by Vidya L Nathan in Bengaluru,; Editing by Don Sebastian

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below